Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: Exenatide and Insulin for Beta-cell Function in Type 2 Diabetes
NCT02194595Phase 3Completed
- Sponsor
- Mount Sinai Hospital
- Start
- Sep 2014
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Mount Sinai Hospital. Started Sep 2014; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02194595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194595.